Amerikanische Gesellschaft für Hirudotherapie

Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention

Review published in Progress in cardiovascular diseases (1997)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienLefkovits J · Progress in cardiovascular diseases, 1997

Abstract

A large number of drug trials for prevention of restenosis have been conducted with many showing little or conflicting benefit. Antiplatelets such as aspirin, ticlopidine and thromboxane A2 receptor inhibitors have not shown a clear benefit. Similarly, antithrombotics, either acting indirectly such as heparin, or as direct thrombin inhibitors such as hirudin and hirulog, do not prevent restenosis. Trials with ACE inhibitors, HMG-CoA reductase inhibitors and fish-oil supplements have yielded inconclusive results. The antiproliferatives, angiopeptin, trapidil and tranilast have shown some benefit in small-scale studies. Other drug classes of potential benefit include the glycoprotein IIb/IIIa receptor antagonists, inhibitors of the early coagulation cascade, calcium channel blockers and nitric oxide donors. Drug research into restenosis prevention has been hampered by problems with the definition of restenosis and the applicability in humans of animal models. Although no single drug has conclusively proven effective yet, the promise of a number of agents, together with other nonpharmacological strategies will likely result in further reductions in the incidence of restenosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAbciximabAngioplasty, Balloon, CoronaryAngiotensin-Converting Enzyme InhibitorsAnimalsAntibodies, MonoclonalAnticoagulantsCardiovascular AgentsConstriction, PathologicCoronary AngiographyCoronary DiseaseCoronary VesselsDisease Models, Animal

Zusammenfassung

A large number of drug trials for prevention of restenosis have been conducted with many showing little or conflicting benefit.

Warum dies für die Hirudotherapie relevant ist

This review summarizes drug trials for the prevention of restenosis, noting that many have shown little or conflicting benefit. The abstract states that direct thrombin inhibitors such as hirudin and hirulog 'do not prevent restenosis,' alongside similar negative findings for antiplatelets and inconclusive results for ACE inhibitors and other agents. The abstract characterizes hirudin only as a direct thrombin inhibitor and does not mention leeches, leech saliva, or hirudotherapy. The article offers no information connecting hirudin to leeches or to ASH's domain of live leech therapy; it merely lists hirudin among drugs that failed to prevent restenosis.

Zitation

Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention

Lefkovits J · Progress in cardiovascular diseases, 1997

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.